

Bosulif - (100,500 mg; Tablet, Oral)

Generic Name	Bosutinib	Innovator	Pfizer
Dosage	100,500 mg; Tablet, Oral	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	Less Than 5	Generic Launches	None
Indication	Indicated for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Bosulif - (400 mg, tablet, oral)

Generic Name	Bosutinib	Innovator	Pfizer
Dosage	400 mg, tablet, oral	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	Indicated for the treatment of adult patients with newly-diagnosed chronic phase Ph+ chronic myelogenous leukemia (CML) as well as for chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Bosulif - (50MG, 100MG)

Generic Name	Bosutinib	Innovator	None
Dosage	50MG, 100MG	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	BOSULIF is a kinase inhibitor indicated for the treatment of (1) adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly diagnosed or resistant or intolerant to prior therapy. (2) Adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Bosulif - (50MG, 100MG, 500MG)

Generic Name	Bosutinib	Innovator	None
Dosage	50MG, 100MG, 500MG	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	BOSULIF is a kinase inhibitor indicated for the treatment of (1) adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly diagnosed or resistant or intolerant to prior therapy. (2) Adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.